Background: The treatment of vancomycin-resistant enterococcal (VRE) bacteraemia remains challenging. Daptomycin is a new antibiotic with bactericidal activity against VRE, but available clinical data are limited.
Introduction
Vancomycin-resistant enterococci (VRE) emerged in the late 1980s and resistance to vancomycin is now found in 60% of Enterococcus faecium isolates causing nosocomial bloodstream infections (BSIs) encountered in US healthcare institutions. 1 Two different meta-analyses have shown that vancomycin resistance is an independent predictor of death among patients with enterococcal BSIs. 2, 3 Despite this, few effective antibiotics are approved by the US Food and Drug Administration (FDA) for the treatment of serious VRE infections.
Quinupristin/dalfopristin, approved in 1999, was the first antibiotic for the treatment of VRE bacteraemia. 4 The clinical use of quinupristin/dalfopristin was limited because of its adverse effects profile, need for a central line and because of its lack of coverage against Enterococcus faecalis. Linezolid, the first of a new class of synthetic antimicrobials named the oxazolidinones and the second agent approved by the FDA (in April 2000) to treat VRE infections, quickly replaced the use of quinupristin/ dalfopristin because of a more favourable side effect profile, oral bioavailability and coverage against E. faecalis. The widespread use of linezolid was quickly associated with descriptions of linezolid-resistant VRE cases with subsequent reports of nosocomial transmission of linezolid-resistant VRE in hospitals. 4 -6 Furthermore, linezolid is a bacteriostatic agent and concerns have been raised regarding the long-term (.2 weeks) administration of the drug because of potential bone marrow toxicity and neuropathy. 7 Daptomycin is a cyclic lipopeptide derived from Streptomyces roseosporus as a fermentation product and has rapid concentration-dependent bactericidal activity against most Gram-positive pathogens, including those with multidrug resistance. 8 -10 The FDA approved daptomycin in September 2003 for the treatment of skin and soft tissue infections including vancomycin-susceptible E. faecalis, but not VRE or E. faecium.
11 Daptomycin has shown very good activity against a diverse collection of VRE species in vitro in various studies. 12 -14 However, clinical data supporting the use of daptomycin in the treatment of VRE infections are limited to a few case reports and case series. 15 -18 In order to evaluate the role of daptomycin in the treatment of VRE BSI, we conducted a retrospective study of patients admitted to two tertiary care hospitals in New Orleans, LA, USA to compare the clinical outcomes between linezolid and daptomycin.
Patients and methods

Study design
Patients with a diagnosis of VRE BSI were identified by infection control and/or microbiology records of the participating institutions, Tulane University Health Sciences Center and Oschner Clinic Foundation, both in New Orleans, LA, USA. The institutional review boards approved this study at both institutions. The study investigators conducted a retrospective study of all patients identified with a diagnosis of VRE BSI and reviewed inpatient hospital records and electronic databases to obtain the demographic and clinical characteristics of the patient population.
Case definition and evaluation
All adult cases (age .18 years) with a diagnosis of VRE BSI, who were treated with either daptomycin or linezolid and admitted to the hospitals between September 2003 and December 2007, were included in the study. VRE BSI was defined as the presence of one or more positive blood cultures for VRE that met the CDC definition of enterococcal BSI. 18 Nosocomial BSI was defined as the isolation of the pathogen after 72 h of hospitalization. 18 Other BSI was defined as the isolation of pathogens other than VRE BSI during the hospital stay. Duration of the bacteraemia was defined as the time interval between the first positive blood culture and the first negative blood culture for VRE BSI. Endocarditis was defined according to Duke's criteria. 19 Catheter-related BSI was defined as the presence of a positive catheter tip and blood culture obtained through the catheter with the isolation of VRE BSI or the isolation of the VRE BSI in the presence of an intravascular catheter and absence of any other source of infection.
18
Baseline demographic and clinical characteristics were obtained for all patients. Co-morbidity was measured using the Charlson scale and a score of 2 was considered to indicate significant co-morbid conditions. 20 Severity of illness was assessed by the APACHE II score. 21 Antimicrobial susceptibility testing of ampicillin, vancomycin and aminoglycosides was performed at the respective institutions' microbiology laboratories following CLSI guidelines. 22 Daptomycin or linezolid susceptibilities were not routinely determined for all VRE specimens in these institutions. Vancomycin resistance was determined by the laboratory if the MIC of vancomycin was 16 mg/L.
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A microbiological cure was defined as the clearance of bacteraemia for at least 2 weeks during or after the institution of the antimicrobials directed to treat VRE BSI. A microbiological failure was defined as the absence of a repeat negative blood culture or death due to sepsis during the time the patient was receiving the antimicrobials directed against the VRE BSI. In-hospital death was defined as death due to any cause during hospitalization. Relapse was defined as the occurrence of a phenotypically similar organism in the blood culture after the end of treatment based on the susceptibility patterns. An active antimicrobial was defined as an antibiotic with in vitro activity (susceptible by MIC) against the VRE BSI. An adverse effect was assessed as being present if there was the development of a known adverse event after the initiation of the antimicrobials. Concomitant BSI was defined as the presence of BSI other than VRE prior to or after 14 days of a positive blood culture for VRE.
Outcomes measured were microbiological cure, duration of bacteraemia, in-hospital death, in-hospital stay duration and adverse effect profile. The above outcomes were compared between the two groups who received either daptomycin or linezolid.
Statistical analysis
Separate analyses were conducted for patients treated with daptomycin and linezolid and patient characteristics including demographics and clinical parameters were calculated. The statistical significance of differences in these characteristics was determined using a least-square test and maximum likelihood methods for continuous and categorical variables, respectively. The prevalences of microbial cure, relapse and death were calculated by treatment groups. Multivariable log binomial regression models, adjusted for age, gender, race, Charlson co-morbidity score and concomitant use of aminoglycosides, were used to determine the association of these outcomes with usage of daptomycin in comparison with linezolid. Median duration of bacteraemia and length of stay were determined, and differences between treatment groups were calculated by quintile regression (SAS experimental version, 2005, Cary, NC, USA) after adjusting for the same variables mentioned above. In an adjusted linear regression model, duration of bacteraemia and length of stay were also predicted by the treatment groups. All statistical analyses were performed using SAS version 9.1.3.
Results
One hundred and eight patients with VRE BSI were identified during the study period at both institutions, and 98 patients were evaluated as they received either linezolid or daptomycin. Two patients with VRE BSI had E. faecalis that were susceptible to ampicillin and were not included in the analysis as they did not receive either linezolid or daptomycin as treatment. The other eight patients were excluded because they were treated with other antimicrobials or were not treated for VRE BSI because the primary care physician felt that the positive blood culture was a contaminant and not a true bacteraemia.
Thirty patients received daptomycin and 68 patients received linezolid as the treatment for VRE BSI. Two patients initially were placed on linezolid for VRE urinary tract infection and abdominal wound infection but later developed BSI so were switched to daptomycin and were included with the daptomycin group as it was the intended treatment for VRE BSI. Synergy with gentamicin was noted in 26.5% of VRE isolates and five isolates were susceptible to ampicillin. Four out of five ampicillin-susceptible isolates were E. faecalis but either linezolid or daptomycin was given as treatment for VRE. The rest of the isolates were E. faecium.
Twenty-three stored isolates of VRE from the Ochsner Clinic Foundation were tested retrospectively by Vitek for susceptibility to daptomycin and linezolid. All isolates were susceptible to daptomycin with MICs of 0.25-2 mg/L. All but one of the isolates tested were susceptible to linezolid with MICs of 2 mg/L. Among these isolates, two were E. faecalis. One isolate had intermediate linezolid susceptibility with an MIC of 4 mg/L.
As shown in Table 1 , there were no statistically significant differences in the baseline demographic or clinical characteristics between the daptomycin and linezolid groups except that the median age was higher in the linezolid group. Even though it was not statistically significant, there was a trend towards a higher APACHE score in the linezolid group (P ¼ 0.08) and a higher prevalence of concomitant staphylococcal bacteraemia in the daptomycin group (P ¼ 0.08). Among patients who were treated with linezolid and daptomycin, 29.4% and 53.3%, respectively, were located in intensive care units (P ¼ 0.03).
Endocarditis, defined as an observed vegetation on echocardiogram in the absence of bacteraemia other than VRE, was present in five patients and three of them received linezolid as treatment. One of the two patients who received daptomycin died at the end of 23 days of treatment but also had candidaemia concomitant with VRE endocarditis. One of the three patients who received linezolid for endocarditis died at the end of the seventh day of treatment and the death was not attributed to VRE endocarditis. None of the three surviving patients had relapse and all received at least 28 days of treatment, one with daptomycin and two with linezolid. All patients with endocarditis received medical therapy only as they were not considered to be good surgical candidates. The median duration of treatment with either daptomycin or linezolid was 14 days (range 2 -42) and the median follow-up interval to repeat the blood culture was 2 days for both groups with a range of 1-10 days. Daptomycin was given at 6 mg/kg doses intravenously (iv) in all patients and linezolid was given at 600 mg every 12 h via either the iv or the oral route. Concomitant administration of aminoglycosides was noted in 58.8% of the linezolid group versus 46.7% of the daptomycin group (P ¼ 0.27).
As shown in Table 2 , the prevalence of microbiological cure, relapse and all-cause mortality was not statistically significantly different between the linezolid and daptomycin groups. Furthermore, there were no differences between the groups after adjusting for age, gender, race, concomitant use of aminoglycosides, co-morbidity, APACHE II score and concomitant BSI.
The mean (SD) length of hospitalization was 31 (25) days for the linezolid group compared with 43 (32) days for the daptomycin group, with a marginally significant P value of 0.09. From a multivariate adjusted linear regression model, patients treated with daptomycin had an additional 9.4 days of hospitalization compared with patients treated with linezolid, but this was not statistically significant (P ¼ 0.15). An all-cause in-hospital mortality rate of 20.6% was observed in the linezolid group compared with 26.7% in the daptomycin group. It was difficult to assess what proportion of the mortality rate and length of hospital stay was due to VRE because of the high rate of concomitant BSI with other organisms and associated co-morbidities.
The median duration of bacteraemia, defined as the time to the first negative blood culture, was 3 days for the daptomycin group and 2 days for the linezolid group (P¼0.23). Furthermore, this was corroborated after adjusting for age, gender, race, concomitant use of an aminoglycoside, Charlson co-morbidity score, APACHE II score and other BSI with a linear regression model (P ¼0.86).
As shown in Table 3 , there were no significant differences between the two treatment groups regarding haematological and renal adverse effects. None of the patients in either group developed rhabdomyolysis or elevated creatinine phosphokinase. Also, there were no statistically significant differences in the different interventions (line removal, surgical treatments, mechanical ventilation and use of vasopressors) between the daptomycin and linezolid groups (P . 0.2).
Discussion
This is the largest study to date comparing the efficacy of daptomycin with that of linezolid in VRE bacteraemia. Our retrospective study showed that linezolid and daptomycin had comparable microbiological cure rates, relapse rates and mortality when used for the treatment of VRE BSI. In-hospital length of stay was higher in the daptomycin group, but could not be attributed to VRE BSI as these patients also had multiple co-morbidities and concomitant BSI. Even though our study was not a randomized study, the baseline demographic and clinical characteristics were similar between groups. Also, there were no statistically significant differences between the baseline severity of illness or co-morbidities between the two groups (see Table 1 ). The linezolid compassionate-use programme showed similar outcomes to our study with a 78% and 85.3% clinical and microbiological cure, respectively, for the treatment for VRE bacteraemia. 23 There is much less clinical outcome data with daptomycin. Clinical success rates of 56% (5 of 9) with daptomycin in VRE BSI and 0% (0 of 2) in VRE endocarditis were reported by Segreti et al. 15 In another review of 14 patients with VRE BSI, similar results were reported for daptomycin compared with linezolid for microbiological clearance (100% versus 88%) and mortality (36% and 45%). 17 A smaller case series found that all patients (n¼7) with VRE bacteraemia in the absence of metastatic foci who were treated with daptomycin had successful clinical outcome. 18 Sakoulas et al.
24 reported a 59% clinical success rate (19 of 32) in patients with VRE BSI from the daptomycin registry.
Daptomycin at 6 mg/kg, given iv once daily, was reported to be non-inferior to standard dual therapy comparators (vancomycin or semi-synthetic penicillinase-resistant penicillins, each combined with short-course gentamicin) in a large randomized controlled registrational trial of S. aureus bacteraemia and infective endocarditis. 25 However, such trials comparing daptomycin with linezolid for the treatment of VRE BSI are lacking. Based on the outcomes observed in our retrospective analysis, daptomycin appears to be equivalent to linezolid in terms of microbiological cure, relapse and mortality rate. None of our patients developed myalgia or elevated creatinine phosphokinase, which is a rare but known side effect of daptomycin. Both drugs showed comparable adverse effect profiles. We only evaluated overall-cause mortality because it was difficult to distinguish death due to VRE from death due to concomitant infections and co-morbidities.
The efficacy of daptomycin in enterococcal endocarditis has only been evaluated in a small unpublished study of 30 patients (15 had VRE) sharing a 73% success rate when used with concomitant therapy with vancomycin, gentamicin, cephalosporins and rifampicin. 26 Definite endocarditis as defined by Duke's criteria was present in five patients (all with vegetations on echocardiogram), two of whom received daptomycin. But the success rates cannot be compared between the two drugs as our groups had only a few patients with endocarditis.
The haematological side effect profile of linezolid in our study was slightly higher than that of Phase III clinical studies of linezolid therapy, but this could be due to the exclusion of sicker patients in clinical trials. Regardless, when compared with daptomycin, which is not known to cause haematological side effects, the rate appears comparable to linezolid. 26 -28 This finding could be because bone marrow suppression with linezolid therapy is usually observed after 2 weeks and in our study the median duration of treatment was only 14 days. In a large study of nosocomial pneumonia, equivalent rates of thrombocytopenia were documented in patients treated with either linezolid or vancomycin with a median duration of 10 days. 29 The treatment of VRE BSI continues to be a challenge to physicians and the options are limited due to side effects and emergence of resistance to newer agents. 4 Daptomycin is the only FDA-approved antibiotic with in vitro bactericidal activity against VRE, but clinical data are very limited. This is the largest study to date comparing the outcomes of patients with VRE BSI treated with either daptomycin or linezolid. The present study has several limitations as it is a retrospective analysis and unblinded and thus many variables were not controlled. Concomitant staphylococcal bacteraemia may have influenced the decision of the physicians to use daptomycin. In addition, concomitant antibiotics were administered in most cases and their contribution to observed outcomes could not be evaluated since susceptibility data were not available. Failures were not further evaluated, thus we cannot comment on the development of resistance to these drugs.
Although our analysis has several limitations, it is the largest comparative study between linezolid and daptomycin for the treatment of VRE bacteraemia to our knowledge. In the case of patients intolerant to linezolid, daptomycin may be considered as an alternative for the treatment of VRE bacteraemia. Prospective randomized controlled trials are needed to confirm our findings.
